Ian Gilbert: Professor of Medicinal Chemistry
Head of Division of Biological Chemistry and Drug Discovery
School of Life Sciences, University of Dundee
Head of Chemistry, Drug Discovery Unit
Wellcome Centre for Anti-Infectives Research
My research is focused around Drug Discovery for Neglected Diseases and Novel Targets in the Division of Biological Chemistry and Drug Discovery.
The mainstay of my research is synthetic medicinal chemistry as part of the Drug Discovery Unit (DDU), where I am Head of Chemistry and part of the Senior Management Team. The DDU is a fully integrated, state-of-the-art drug discovery facility with all of the capabilities required for early phase drug discovery: assay development, high throughput screening, cell biology, medicinal chemistry, structural biology, computational chemistry and DMPK.
In the DDU, our goal is to translate life sciences research into therapeutic applications to address unmet medical needs. We aim to establish proof of concept for new drug targets and develop pre-clinical candidates for neglected diseases.
I have particular interests in the following aspects of drug discovery:
1. Neglected diseases, such as human African trypanosomiasis, leishmaniasis, malaria, and bacterial infections
2. Chemical validation of novel targets for which there is little or no precedence for drug discovery
3. Novel approaches to/and paradigms for drug discovery
4. Mode of action studies and target identification.
By discipline, I am a medicinal chemist. My PhD was in synthetic organic chemistry at the University of Cambridge. Following post-doctoral research in medicinal and biological chemistry projects, I established my own research group, focusing on medicinal chemistry at Cardiff University. In 2005, I moved to Dundee, where I helped to establish the Drug Discovery Unit.
Responsibilities include: Head of Division of Biological Chemistry and Drug Discovery, Head of Chemistry of the and member of the Senior Management Team of the Drug Discovery Unit and Wellcome Centre for Anti-Infectives Research, and Director of Antimicrobial Resistance Centre (University of Dundee), member of the ScotCHEM Executive Board.
A novel multiple-stage antimalarial agent that inhibits protein synthesis
Nature, 2015, 522, 315-320
Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma brucei N-Myristoyltransferase Inhibitors: Idenification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis
J Med. Chem, 2014, 57, 9855-9869
Automated design of ligands to polypharmacological profiles
Nature, 2012, 492, 215-22
Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase Inhibitors
ChemMedChem, 2012, 7, 95-106
N-myristoyltransferase inhibitors as new leads to treat sleeping sickness
Nature, 2010, 464, 728-732